GLP-1 Without Insurance: The Cheapest Legitimate Routes, Ranked by Monthly Cost (2026)

Ranked purely by monthly price, the order is: $0 if you qualify for the NovoCare Patient Assistance Program, then roughly $149/month for oral Wegovy at the starting dose, then compounded semaglutide at $149-249/month for lower doses. The $0 route wins on cost but is income-gated; oral Wegovy is the cheapest FDA-approved option anyone can buy outright; compounded undercuts brand cash prices but is not an FDA-approved finished product. Pick the lowest tier you actually qualify for.

Yes — the lowest possible monthly cost is zero through Novo Nordisk's Patient Assistance Program (PAP). To unlock that price you must be a U.S. resident with household income below 400% of the Federal Poverty Level (roughly $62,400 for an individual in 2026) and carry no prescription drug coverage. Your prescriber files the paperwork. Approved patients get brand-name Ozempic at no cost for 12 months, then re-apply each year. It is the single biggest saving on this page, so check eligibility before paying anything.

Your real out-of-pocket number swings wildly depending on which route you take: $0 on PAP, about $149 on oral Wegovy's starting dose, $149-499 on compounded, and $800-1,350 if you walk into a pharmacy and pay the brand cash price with a GoodRx coupon. The list price of a drug is rarely what an informed self-pay patient ends up spending. The whole point of this guide is to move you down that ladder so you pay the lowest legitimate price your situation allows.

Often yes, because a single monthly fee folds the consultation, medication, and check-ins into one predictable price instead of paying each line item separately. Budget telehealth tiers start around $149-299/month for lower-dose compounded semaglutide, which is far below the brand cash price. The catch is that the cheapest bundles use compounded product, so you are trading some safety assurance for the lower number. Compare the all-in monthly cost of a bundle against buying oral Wegovy directly before you commit.

Yes — for the obesity indication, Medicare Part D coverage begins July 2026, which slashes the self-pay cost for eligible seniors who previously paid full freight. Copays and formulary placement vary by plan, and prior authorization will likely apply. The most important cost ceiling is the Inflation Reduction Act's $2,000/year cap on total Part D out-of-pocket spending, which caps your annual GLP-1 exposure no matter how high the list price climbs. Call your Part D plan as coverage opens to confirm the cheapest path.

On paper, yes — Ozempic runs roughly $150/month in Canada, which looks competitive with US oral Wegovy and compounded pricing. But importing prescription drugs is technically illegal under federal law (the FDA has historically used enforcement discretion only for small personal-use amounts), counterfeit product is common in unregulated channels, and you have no recourse if the order goes wrong. Once you factor in that risk, the domestic $149 oral Wegovy and $0 PAP routes usually win on real value, so exhaust those first.

Run the math dose by dose. At the starting dose the prices nearly tie ($149 oral Wegovy vs $149-249 compounded), and when the gap is that small the FDA-approved product is the smarter buy for the money. The compounded advantage only appears at higher maintenance doses, where it can come in well under brand pricing — but you are then paying less for a non-FDA-approved finished product that carries documented safety trade-offs. Use the comparison table above to see exactly where each option lands on cost before deciding.